SecBot SecBot
SECBOTREPLAY Home › Report › OCUL

OCUL · Ocular Therapeutix announced its participation at Clinical Trials at…

Ocular Therapeutix, Inc. · PRESS-RELEASE filed Jun 4, 2026 at 07:00 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Jun 4, 2026 at 07:00 ET

Ocular Therapeutix announced its participation at Clinical Trials at the Summit 2026, where it will present multiple data updates on AXPAXLI (OTX-TKI) including results from the SOL-1 Phase 3 superiority trial in wet AMD and a HELIOS program update in NPDR. The conference presentations are scheduled for June 12-13, 2026, in Las Vegas, with a CEO fireside chat and several clinical sessions.

  • SOL-1 Phase 3 superiority trial efficacy outcomes with OTX-TKI in neovascular AMD to be presented at CTS 2026 on June 13
  • HELIOS program update on OTX-TKI in nonproliferative diabetic retinopathy (NPDR) also scheduled for June 13
  • Safety and tolerability profile of OTX-TKI in neovascular AMD presented separately on the same day
  • Pravin U. Dugel, MD (CEO) participating in fireside chat 'From Global KOL to CEO' and panel 'From Innovation to Approval'

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access